To the Editor.
—In a recent correspondence, the misuse of eye drops due to interchanged caps was presented.1 The authors suggested a system for color-coding the bottle caps and labels of topical ophthalmic medications to decrease the incidence of confusion with similar bottles and the possibility of inadvertently misusing medications. This has been a concern of the Committee of Drugs of the American Academy of Ophthalmology for many years. With support from the Food and Drug Administration, the academy has been successful in receiving commitments from several major manufacturers of eye medications, including Alcon Pharmaceuticals, Fort Worth, Tex; Allergan Pharmaceuticals, Irvine, Calif; IOLab Pharmaceuticals, Claremont, Calif; and Merck Sharpe & Dohme, West Point, Pa, to implement such a color-coding standard for major therapeutic categories. With the help of others in the pharmaceutical industry, it is the intent of these manufacturers to implement the following drug-packaging standards for eye drop
Fraunfelder FT. Drug-Packaging Standards for Eye Drop Medications. Arch Ophthalmol. 1988;106(8):1029. doi:10.1001/archopht.1988.01060140181003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: